Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR
Arrowhead Pharmaceuticals — Technical Presentation
14 slides from Arrowhead Pharmaceuticals's technical presentation

Slide 1: VSA003 (Zodasiran) Reduces LDL-C and Atherogenic Lipoproteins in Chinese HoFH Patients
VSA003 (Zodasiran), a GalNac siRNA Targeting ANGPTL3, Demonstrated Substantial Reductions in LDL-Cholesterol and Multiple Atherogenic Lipoproteins in Chinese Patients with HoFH Presenter: Zhuang TIAN, MD Peking Union Medical College Hospital Authors: Z. Tian, LY. Wang, LW. Li, XP. Ma, Y. Peng, P. Do

Slide 2: Homozygous Familial Hypercholesterolemia: Rare Disease with High Unmet Medical Needs
Homozygous Familial Hypercholesterolemia: Rare Disease with High Unmet Medical Needs HoFH is a Rare But Serious Disease HoFH Patients have High Unmet Medical Needs3 ⚫ Prevalence1: ⚫ Underdiagnosis and undertreatment; 1/300,000 to 1/170,000 worldwide; ⚫ Suboptimal response to conventional ⚫ Extremely

Slide 3: ANGPTL3: a Key Regulator of Lipoprotein Disposition
ANGPTL3: a Key Regulator of Lipoprotein Disposition VSA003 Figure adapted from the presentation of GATEWAY study in 2025 EAS Congress. 1. Adam, et al. J Lipid Res. 2020;61(9): 1271-86. 2. Rosenson. J Lipid Res. 2021:62:100060. 3. Dewey, et al. N Engl J Med. 2017;377 (3):211-21. 4. Minicocci, et al.

Slide 4: Overview of VSA003 and Development Program
Overview of VSA003 and Development Program VSA003, a synthetic double-stranded, liver-targeted NAG-conjugated small RNA interference therapeutic designed to target mRNA transcripts from ANGPTL3 gene, inhibits ANGPTL3 expression and reduces atherogenic lipoproteins through mechanisms independent of t

Slide 5: A Phase 3 Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese Adolescents and Adults with HoFH
A Phase 3 Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese Adolescents and Adults with HoFH Trial Design Key Milestone Population Endpoints • Aged ≥12 years with genetically or • Primary Efficacy Endpoint: percent change from baseline to M6 in fasting LDL-C vs. placebo clinically confi

Slide 6: Baseline Characteristics
Baseline Characteristics Baseline Characteristics Enrolled Placebo (N=16) VSA003 (N=30) Age (years), mean (SD) 31.6 (13.5) 36.0 (11.8) 12-17 yrs 2 (12.5) 2 (6.7) Age group, n(%) ≥18 yrs 14 (87.5) 28 (93.3) Female, n(%) 10 (62.5) 21 (70.0) Body Mass Index (kg/m2), mean (SD) 23.1 (4.0) 22.6 (3.6) LDL-

Slide 7: Over 43.9% Reduction in LDL-C versus placebo by Month 6
Over 43.9% Reduction in LDL-C versus placebo by Month 6 LDL-C change over time (Primary Endpoint) Statistics Placebo VSA003 LS Mean Difference (SE) vs. Placebo, P value LS Mean (SE) Percent Change from BL at M6 (MI), % -0.9 (4.3) -44.8 (3.2) -43.9 (5.2), P<0.0001 LS Mean (SE) Change from BL at M6 (M

Slide 8: Rapid and Substantial Reduction in ANGPTL3
Rapid and Substantial Reduction in ANGPTL3 ANGPTL3 change over time (Target) Placebo VSA003 LS Mean Difference (SE) vs. Placebo, P value LS Mean (SE) Percent Change from BL at M6 (MI), % -3.2 (5.3) -89.4 (4.2) -86.2 (6.6), P<0.0001 ANGPTL3, angiopoietin-like protein 3

Slide 9: Significantly Reduced Atherogenic Lipid and Lipoproteins
Significantly Reduced Atherogenic Lipid and Lipoproteins non-HDL-C ApoB Percent Change from BL at M6 (%) (MI) Percent Change from BL at M6 (%) (MI) P value P value LS Mean Difference (SE) vs. Placebo LS Mean Difference (SE) vs. Placebo -42.6 (5.1) P<0.0001 -32.6 (4.3) P<0.0001 TG Lp(a) Percent Chang

Slide 10: 83.3% of Patients Treated With VSA003 Achieved LDL-C Reduction ≥30% by Month 6
83.3% of Patients Treated With VSA003 Achieved LDL-C Reduction ≥30% by Month 6 Placebo VSA003 Percent change of individuals in LDL-C from baseline at M6, %

Slide 11: Consistent LDL-C Reductions Across Prespecified Subgroups
Consistent LDL-C Reductions Across Prespecified Subgroups VSA003 vs Placebo Patients No. LDL-C percent change from Baseline (%) Subgroup VSA003/Placebo LS mean difference (95% CI) All Subjects Concomitant PCSK9i use Yes No Sex Male Female Age 12-17yrs ≥18yrs Body Mass Index <25 kg/m2 ≥25 kg/m2 LDL-C

Slide 12: Well-Tolerated and Favorable Safety Profile
Well-Tolerated and Favorable Safety Profile • Treatment-emergent adverse events (TEAEs) were comparable between two groups; • Study drug-related TEAEs were predominantly mild in severity, mainly injection site reactions and liver findings; • No study drug-related serious AEs. Placebo (N = 16) VSA003

Slide 13: Conclusion
Conclusion • VSA003 demonstrated a significant reduction in LDL-C by 43.9% (5.2) vs. placebo in Chinese patients with HoFH; • VSA003 substantially reduced other atherogenic lipids and lipoproteins, including ApoB, non-HDL-C, TG, and Lp(a); • VSA003 was well tolerated and demonstrated a favorable saf

Slide 14: Acknowledgements
Acknowledgements We would like to thank the patients and caregivers who participated in this study. No Principal Investigator Site Zhuang Tian 1 Shuyang Zhang* Peking Union Medical College Hospital, Beijing 2 Luya Wang Suzhou Municipal Hospital, Suzhou 3 Liwen Li Guangdong Provincial People's Hospit
Source: company website
More decks from Arrowhead Pharmaceuticals, Inc.
Technical Presentation (October 2026)47 slides · Oct 14, 2026
Technical Presentation (June 2026)57 slides · Jun 29, 2026
Technical Presentation (January 2026)65 slides · Jan 6, 2026
TIDES USA 202626 slides · 2026
Investor Presentation (December 2025)38 slides · December 2025
Corporate Update (November 2025)43 slides · Nov 18, 2025